Agreement Signed for Planning of Proposed Ph 3 Trial of Ampligen for Late-Stage Pancreatic Cancer March 10, 2026
FDA places partial clinical hold on Ph 2 LINNET study of lorigerlimab in patients with gynecologic cancers March 3, 2026
First Patient Dosed in Ph 2 MOMENTUM Trial of Cemsidomide in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma March 3, 2026
First Patient Dosed in Ph 2 Study of Givastomig-Nivolumab combo in Patients with 1L Metastatic HER2-neg Gastric Cancer February 25, 2026
Planned Milestones in Ongoing Ph 2 DURIPANC Trial of Ampligen and Durvalumab in the Treatment of Metastatic Pancreatic Cancer Announced February 25, 2026
First patient dosed in the PiNACLE – H2H Ph 3 trial of rondecabtagene autoleucel (ronde-cel or LYL314) vs liso-cel or axi-cel in 2L R/R LBCL February 17, 2026
First Patient Enrolled in Global Ph 1 Trial of AN9025 for Solid Tumors Harboring RAS Mutations February 17, 2026
Patient recruitment opened for Ph 1 trial of Innocell in patients with recurrent epithelial ovarian cancer February 9, 2026
Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma February 9, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
Key Patent Filed and Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors Unveiled February 1, 2026
